Royalty Pharma (RPRX) Free Cash Flow Growth (1y) (2020 - 2026)
Royalty Pharma (RPRX) Free Cash Flow Growth (1y) (2020 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
FCF Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
60.84% |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
88.70% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
- |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-15.72% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
66.37% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Royalty Pharma |
23.13 Bn |
25.57 Bn |
- |
-55.32% |
| Date | Value |
|---|
| Mar 31, 2026 |
-55.32% |
| Dec 31, 2025 |
-62.02% |
| Sep 30, 2025 |
47.19% |
| Jun 30, 2025 |
615.30% |
| Mar 31, 2025 |
2.85% |
| Dec 31, 2024 |
207.18% |
| Sep 30, 2024 |
-501.15% |
| Jun 30, 2024 |
-112.86% |
| Mar 31, 2024 |
33.88% |
| Dec 31, 2023 |
-171.82% |
| Sep 30, 2023 |
115.74% |
| Jun 30, 2023 |
36.86% |
| Mar 31, 2023 |
-6.10% |
| Dec 31, 2022 |
0.46% |
| Sep 30, 2022 |
10.25% |
| Jun 30, 2022 |
13.93% |
| Mar 31, 2022 |
1,898.20% |
| Dec 31, 2021 |
232.88% |
| Sep 30, 2021 |
-195.03% |
| Jun 30, 2021 |
2,467.27% |
